Severe outcomes of COVID-19 among adults with increased risk conditions: A population-based observational study.
<h4>Background</h4>The individual risk of severe outcomes following COVID-19 is poorly understood in populations with prior immunity. The lack of contemporary estimates limits support of timely diagnosis and antiviral treatment for individuals most likely to benefit.<h4>Objective&l...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0316529 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <h4>Background</h4>The individual risk of severe outcomes following COVID-19 is poorly understood in populations with prior immunity. The lack of contemporary estimates limits support of timely diagnosis and antiviral treatment for individuals most likely to benefit.<h4>Objective</h4>To determine the risk of severe outcomes following COVID-19 within strata of comorbidities, including patients without documented infection.<h4>Design</h4>Population-based cohort study utilizing electronic medical records and g methods to account for selection bias in the documentation of COVID-19 illnesses.<h4>Setting</h4>A large health system in northeastern United States.<h4>Patients</h4>Adults with increased risk conditions (90% vaccinated) and COVID-19 from June to December 2022.<h4>Measurements</h4>Incidence of composite of inpatient admission within 14 days and death within 28 days of COVID-19 diagnosis.<h4>Results</h4>An estimated 265,248 patients with at least one increased risk condition developed COVID-19, including 76,996 documented cases. Severe outcomes occurred in 3344 (1.3%) patients following COVID-19- 3147 (1.2%) hospitalizations and 376 (0.14%) deaths. In the absence of treatment, individuals with few increased risk conditions (MASS of 3 or less) accounted for 57% of infections and 0.7% developed severe outcomes. In contrast, 2.3% of patients with multiple increased risk conditions (MASS 4 or greater) or severe immunocompromise experienced severe outcomes, including 81% of deaths. The observed risk reduction with antiviral treatment was -0.1% (-0.2 to 0.02%), -0.6% (-0.9 to -0.4%), -1.3% (-2 to -1%), and -1.9% (-3 to -1%) for patients with MASS 3 or less, MASS 4 and 5, MASS 6 or greater, and severe immunocompromise, respectively.<h4>Limitations</h4>Estimated number COVID-19 cases cannot be directly verified.<h4>Conclusions</h4>Individuals with multiple medical conditions remain at substantial risk for severe outcomes of COVID-19 and benefit from treatment. |
|---|---|
| ISSN: | 1932-6203 |